Abstract
To investigate the effect of simvastatin on the migration and invasion of fibroblast-like synoviocytes (FLS) from patients with rheumatoid arthritis (RA) and its cellular signal mechanisms, FLS from active RA patients were stimulated with 3 % FBS or GM-CSF in the presence or absence of simvastatin. Cells migration and invasion in vitro were measured by the Boyden chamber method. RhoA activity was assessed by a pull-down assay. Matrix metalloproteinases-2 (MMP-2) activity was evaluated by zymography. Simvastatin inhibits FBS- or GM-CSF-induced migration in a dose-dependent manner by RA FLS, and this inhibitory effect is independent of cell apoptosis. We also found that simvastatin suppressed in vitro invasion, adhesion, MMP-2 activity, cytoskeletal reorganization and RhoA activation. Furthermore, mevalonate or GGPP treatment reversed the inhibitory effect of simvastatin not only on migration and invasion in vitro but also on RhoA activation, and inhibition of RhoA by specific siRNA transfection reduced migration, adhesion and invasion of RA FLS. This study shows that simvastatin reduces RA FLS migration and invasion through the prevention of protein geranylgeranylation and RhoA activation. These findings provide a novel evidence that statin may be benefit for preventing RA arthritic destruction, and also indicate that RhoA may be a new target for the modulation of RA FLS migration and invasion.
Similar content being viewed by others
References
Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–916
Gravallese EM (2002) Bone destruction in arthritis. Ann Rheum Dis 61:(Suppl 2):ii84–ii86
Skapenko A, Leipe J, Lipsky PE, Schulze-Koops H (2005) The role of the T cell in autoimmune inflammation. Arthritis Res Ther 7(Suppl 2):S4–S14
Ma Y, Pope RM (2005) The role of macrophages in rheumatoid arthritis. Curr Pharm Des 11:569–580
Firestein GS, Echeverri F, Yeo M, Zvaifler NJ, Green DR (1997) Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 94:10895–10900
Roivainen A, Jalava J, Pirila L, Yli-Jama T, Tiusanen H, Toivanen P (1997) H-ras oncogene point mutation in arthritic synovium. Arthritis Rheum 40:1636–1643
Müller-Ladner U, Pap T, Gay RE, Neidhart M, Gay S (2005) Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Clin Pract Rheumatol 1:102–110
Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T (2006) Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology 45:669–675
Müller-Ladner U, Kriegsmann J, Franklin BN, Matsumoto S, Geiler T, Gay RE et al (1996) Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 149:1607–1615
Pap T, Meinecke I, Muller-Ladner U, Gay S (2005) Are fibroblasts involved in joint destruction? Ann Rheum Dis 64(Suppl 4):iv52–iv54
Lefèvre S, Knedlal A, Tenniel C, Kampmann A, Wunrau C, Dinser R et al (2009) Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat Med 15:1414–1420
Greenwood J, Steinman L, Zamvil SS (2006) Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 6:358–370
Casey PJ (1995) Protein lipidation in cell signaling. Science 268:221–225
Goldstein JL, Brown MS (1990) Regulation of mevalonate pathway. Nature 343:425–430
Scita G, Tenca P, Frittoli E (2000) Signaling from Ras to Rac and beyond: not just a matter of GEFs. EMBO J 19:2393–2398
Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, Baranda L, Cruz-Rizo J, Gonzalez-Amaro R (2003) Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 12:607–611
McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I et al (2004) Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363:2015–2021
Tikiz C, Utuk O, Pirildar T, Bayturan O, Bayindir P, Taneli F et al (2005) Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with long term rheumatoid arthritis. J Rheumatol 32:2095–2101
Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H et al (2003) A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 170:1524–1530
Xu H, Liu P, Liang L, Danesh FR, Yang X, Ye Y et al (2006) RhoA-mediated, tumor necrosis factor α-induced activation of NF-κB in rheumatoid synoviocytes: inhibitory effect of simvastatin. Arthritis Rheum 54:3441–3451
Barsante MM, Roffe E, Yokoro CM, Tafuri WL, Souza DG, Pinho V et al (2005) Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. Eur J Pharmacol 516:282–289
Yamagata T, Kinoshita K, Nozaki Y, Sugiyama M, Ikoma S, Funauchi M (2007) Effects of pravastatin in murine collagen induced arthritis. Rheumatol Int 27:631–639
Danesh FR, Sadeghi MM, Amro N, Philips C, Zeng L, Sahai A et al (2002) 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors prevent high glucose induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: implications for diabetic nephropathy. Proc Natl Acad Sci USA 99:8301–8305
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324
Wang AZ, Chen JM, Fisher GW, Wang JC, Diamond HS (1994) Improved in vitro models for assay of rheumatoid synoviocyte chemotaxis. Clin Exp Rheumatol 12:293–299
Nagashima T, Okazaki H, Yudoh K, Matsuno H, Minota S (2006) Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis. Arthritis Rheum 54:579–586
Litinsky I, Golan I, Yaron M, Yaron I, Caspi D, Elkayam O (2009) Simvastatin induces apoptosis of fibroblast-like synoviocytes. Open Rheumatol J 3:35–40
Yokota K, Miyoshi F, Miyazaki T, Sato K, Yoshida Y, Asanuma Y et al (2008) High concentration simvastatin induces apoptosis in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol 35:193–200
John A, Tuszynski G (2001) The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7:14–23
McMahon M, Brahn E (2008) Inflammatory lipids as a target for therapy in the rheumatic diseases. Expert Opin Investig Drugs 17:1213–1224
Chodick G, Amital H, Shalem Y, Kokia E, Heymann AD, Porath A et al (2010) Persistence with statins and onset of rheumatoid arthritis: a population-based cohort study. PLoS Med 7:e1000336
Wahane VD, Kumar VL (2010) Atorvastatin ameliorates inflammatory hyperalgesia in rat model of monoarticular arthritis. Pharmacol Res 61:329–333
Ikeda T, Nakamura K, Akagi S, Kusano KF, Matsubara H, Fujio H et al (2010) Inhibitory effects of simvastatin on platelet-derived growth factor signaling in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. J Cardiovasc Pharmacol 55:39–48
Jougasaki M, Ichiki T, Takenoshita Y, Setoguchi M (2010) Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells. Br J Pharmacol 159:1294–1303
Montecucco F, Burger F, Pelli G, Poku NK, Berlier C, Steffens S et al (2009) Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes. Rheumatology 48:233–242
Maher BM, Dhonnchu TN, Burke JP, Soo A, Wood AE, Watson RW (2009) Statins alter neutrophil migration by modulating cellular Rho activity–a potential mechanism for statins-mediated pleotropic effects? J Leukoc Biol 85:186–193
Fromigué O, Hamidouche Z, Marie PJ (2008) Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. J Biol Chem 283:30549–30556
Aznar S, Lacal JC (2001) Rho signals to cell growth and apoptosis. Cancer Lett 165:1–10
Volin MV, Huynh N, Klosowska K, Chong KK, Woods JM (2007) Fractalkine is a novel chemoattractant for rheumatoid arthritis fibroblast-like synoviocyte signaling through MAP kinases and Akt. Arthritis Rheum 56:2512–2522
Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E et al (2000) Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 43:250–258
Acknowledgments
The authors would like to thank Yanlong Yang and Xiuqing Dong for their technical assistance. This work is supported by grants from National Natural Science Foundation of China (grant number u0772001 and 81072484), Ministry of Education Foundation, China (grant number 20100171110058), Guangdong Natural Science Foundation (grant number 2011020002358) and Guangdong Project of Science and Technology (grant number 2011B080701011, 2008B080703015).
Conflict of interest
No conflict of interest has been declared by authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
Youjun Xiao, Liuqin Liang and Yunfeng Pan contributed equally to this work.
Rights and permissions
About this article
Cite this article
Xiao, Y., Liang, L., Pan, Y. et al. Inhibitory effects of simvastatin on migration and invasion of rheumatoid fibroblast-like synoviocytes by preventing geranylgeranylation of RhoA. Rheumatol Int 33, 389–399 (2013). https://doi.org/10.1007/s00296-012-2383-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-012-2383-7